MARKET

ALIM

ALIM

Alimera Sciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.00
+0.69
+8.30%
After Hours: 9.00 0 0.00% 16:42 03/02 EST
OPEN
8.26
PREV CLOSE
8.31
HIGH
9.03
LOW
8.21
VOLUME
91.55K
TURNOVER
--
52 WEEK HIGH
10.79
52 WEEK LOW
2.860
MARKET CAP
51.47M
P/E (TTM)
-8.5722
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Alimera Sciences to Present at the H.C. Wainwright Global Life Sciences Conference
ATLANTA, March 02, Mar 02, 2021 (GLOBE NEWSWIRE via COMTEX) -- ATLANTA, March 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"),...
GlobeNewswire · 19h ago
Alimera (ALIM) Gets a Buy Rating from H.C. Wainwright
SmarterAnalyst · 4d ago
Intravitreal (IVT) Injectables Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
The Global is poised to register a CAGR of over 4.7% during the forecast period 2020 to 2027.
Market Insight Reports · 5d ago
Ocular Inflammation Therapeutics Market Analysis, Size, Share, Trends and Forecast 2020-2027
pune, India, Thu, 25 Feb 2021 01:14:06 / Comserve Inc. / -- Ocular Inflammation Therapeutics market to help players in achieving a strong market position....
Comserve · 6d ago
8-K: ALIMERA SCIENCES INC
(EDGAR Online via COMTEX) -- alim-20210224x8k false000126760200012676022021-02-242021-02-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C....
Edgar Online - (EDK = 8-Ks/S1/S-4) · 6d ago
BRIEF-Alimera Sciences Reports Fourth Quarter And 2020 Results
reuters.com · 6d ago
Alimera Sciences Q4 EPS $(0.18) Misses $(0.04) Estimate, Sales $13.80M Beat $13.43M Estimate
Alimera Sciences (NASDAQ:ALIM) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.04) by 350 percent. This is a 325 percent decrease over earnings of $0.08 per share from
Benzinga · 6d ago
Alimera Sciences 4Q Rev $13.8M >ALIM
Alimera Sciences 4Q Rev $13.8M >ALIM
Dow Jones · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALIM. Analyze the recent business situations of Alimera Sciences through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALIM stock price target is 14.25 with a high estimate of 18.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 55
Institutional Holdings: 31.41M
% Owned: 549.19%
Shares Outstanding: 5.72M
TypeInstitutionsShares
Increased
6
469.90K
New
6
20.06K
Decreased
1
86.64K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.38%
Pharmaceuticals & Medical Research
-0.88%
Key Executives
Non-Executive Chairman
C. Daniel Myers
President/Chief Executive Officer/Director
Richard Eiswirth
Chief Financial Officer
Phil Jones
Chief Operating Officer/Senior Vice President
Philip Ashman
Senior Vice President/Chief Marketing Officer
David Holland
Other
Samer Kaba
Lead Director/Independent Director
James Largent
Independent Director
Brian Halak
Independent Director
Garheng Kong
Independent Director
Peter Pizzo
Independent Director
John Snisarenko
Independent Director
Mary Szela
  • Dividends
  • Splits
  • Insider Activity
No Data
About ALIM
Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through U.S. and International segment. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, Canada, Lebanon and the United Arab Emirates, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

Webull offers kinds of Alimera Sciences Inc stock information, including NASDAQ:ALIM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALIM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALIM stock methods without spending real money on the virtual paper trading platform.